390 related articles for article (PubMed ID: 19280622)
1. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy.
Tenney DJ; Rose RE; Baldick CJ; Pokornowski KA; Eggers BJ; Fang J; Wichroski MJ; Xu D; Yang J; Wilber RB; Colonno RJ
Hepatology; 2009 May; 49(5):1503-14. PubMed ID: 19280622
[TBL] [Abstract][Full Text] [Related]
2. Entecavir resistance is rare in nucleoside naïve patients with hepatitis B.
Colonno RJ; Rose R; Baldick CJ; Levine S; Pokornowski K; Yu CF; Walsh A; Fang J; Hsu M; Mazzucco C; Eggers B; Zhang S; Plym M; Klesczewski K; Tenney DJ
Hepatology; 2006 Dec; 44(6):1656-65. PubMed ID: 17133475
[TBL] [Abstract][Full Text] [Related]
3. Two-year assessment of entecavir resistance in Lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present.
Tenney DJ; Rose RE; Baldick CJ; Levine SM; Pokornowski KA; Walsh AW; Fang J; Yu CF; Zhang S; Mazzucco CE; Eggers B; Hsu M; Plym MJ; Poundstone P; Yang J; Colonno RJ
Antimicrob Agents Chemother; 2007 Mar; 51(3):902-11. PubMed ID: 17178796
[TBL] [Abstract][Full Text] [Related]
4. A case of entecavir resistance which is developed after complete viral suppression during entecavir treatment for nucleoside-naive chronic hepatitis B.
Doğan ÜB; Öztürk AB; Akın MS; Yalaki S; Sayan M
Turk J Gastroenterol; 2014 Dec; 25 Suppl 1():206-9. PubMed ID: 25910308
[TBL] [Abstract][Full Text] [Related]
5. Mechanistic characterization and molecular modeling of hepatitis B virus polymerase resistance to entecavir.
Walsh AW; Langley DR; Colonno RJ; Tenney DJ
PLoS One; 2010 Feb; 5(2):e9195. PubMed ID: 20169198
[TBL] [Abstract][Full Text] [Related]
6. [Entecavir resistance in entecavir naive lamivudine treated chronic hepatitis B patients].
Sayan M; Hülagü S; Akhan SC; Sentürk O; Meriç M; Cekmen M
Mikrobiyol Bul; 2009 Jul; 43(3):425-32. PubMed ID: 19795617
[TBL] [Abstract][Full Text] [Related]
7. Simultaneous emergence of entecavir resistance mutations in a nucleoside-naive chronic hepatitis B patient.
Lee HW; Kim HJ; Hong SP; Cha BK; Chang HY; Choi CH; Do JH; Kim JG; Chang SK
Intervirology; 2012; 55(5):380-4. PubMed ID: 22538265
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of entecavir in lamivudine-refractory patients with chronic hepatitis B: randomized controlled trial in Japanese patients.
Suzuki F; Toyoda J; Katano Y; Sata M; Moriyama M; Imazeki F; Kage M; Seriu T; Omata M; Kumada H
J Gastroenterol Hepatol; 2008 Sep; 23(9):1320-6. PubMed ID: 18554238
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive evaluation of hepatitis B virus reverse transcriptase substitutions associated with entecavir resistance.
Baldick CJ; Tenney DJ; Mazzucco CE; Eggers BJ; Rose RE; Pokornowski KA; Yu CF; Colonno RJ
Hepatology; 2008 May; 47(5):1473-82. PubMed ID: 18435459
[TBL] [Abstract][Full Text] [Related]
10. Mechanism of entecavir resistance of hepatitis B virus with viral breakthrough as determined by long-term clinical assessment and molecular docking simulation.
Mukaide M; Tanaka Y; Shin-I T; Yuen MF; Kurbanov F; Yokosuka O; Sata M; Karino Y; Yamada G; Sakaguchi K; Orito E; Inoue M; Baqai S; Lai CL; Mizokami M
Antimicrob Agents Chemother; 2010 Feb; 54(2):882-9. PubMed ID: 19933798
[TBL] [Abstract][Full Text] [Related]
11. Dynamics of hepatitis B virus resistance substitutions correlates with virological response in lamivudine-refractory patients with entecavir rescue monotherapy.
Zhang Y; He S; Li QL; Guo JJ
Virus Res; 2013 Nov; 177(2):156-62. PubMed ID: 23968804
[TBL] [Abstract][Full Text] [Related]
12. Hepatitis B virus polymerase variants associated with entecavir drug resistance in treatment-naive patients.
Jardi R; Rodriguez-Frias F; Schaper M; Ruiz G; Elefsiniotis I; Esteban R; Buti M
J Viral Hepat; 2007 Dec; 14(12):835-40. PubMed ID: 18070286
[TBL] [Abstract][Full Text] [Related]
13. Entecavir therapy for lamivudine-refractory chronic hepatitis B: improved virologic, biochemical, and serology outcomes through 96 weeks.
Sherman M; Yurdaydin C; Simsek H; Silva M; Liaw YF; Rustgi VK; Sette H; Tsai N; Tenney DJ; Vaughan J; Kreter B; Hindes R;
Hepatology; 2008 Jul; 48(1):99-108. PubMed ID: 18537189
[TBL] [Abstract][Full Text] [Related]
14. [A double-blind, double-dummy, randomized, controlled study of entecavir versus lamivudine for treatment of chronic hepatitis B].
Yao GB; Zhu M; Wang YM; Xu DZ; Tan DM; Chen CW; Hou JL
Zhonghua Nei Ke Za Zhi; 2006 Nov; 45(11):891-5. PubMed ID: 17313873
[TBL] [Abstract][Full Text] [Related]
15. Antiviral efficacy of combination therapy with entecavir and adefovir for entecavir/lamivudine-resistant hepatitis B virus with or without adefovir resistance.
Yang HJ; Lee JH; Kim YJ; Yoon JH; Lee HS
J Med Virol; 2012 Mar; 84(3):424-30. PubMed ID: 22246827
[TBL] [Abstract][Full Text] [Related]
16. Response to tenofovir monotherapy in chronic hepatitis B patients with prior suboptimal response to entecavir.
Pan CQ; Hu KQ; Yu AS; Chen W; Bunchorntavakul C; Reddy KR
J Viral Hepat; 2012 Mar; 19(3):213-9. PubMed ID: 22329376
[TBL] [Abstract][Full Text] [Related]
17. Low efficacy of entecavir therapy in adefovir-refractory hepatitis B patients with prior lamivudine resistance.
Cho SW; Koh KH; Cheong JY; Lee MH; Hong SP; Yoo WD; Kim SO
J Viral Hepat; 2010 Mar; 17(3):171-7. PubMed ID: 19678894
[TBL] [Abstract][Full Text] [Related]
18. Antiviral effect of entecavir in chronic hepatitis B: influence of prior exposure to nucleos(t)ide analogues.
Reijnders JG; Deterding K; Petersen J; Zoulim F; Santantonio T; Buti M; van Bömmel F; Hansen BE; Wedemeyer H; Janssen HL;
J Hepatol; 2010 Apr; 52(4):493-500. PubMed ID: 20185191
[TBL] [Abstract][Full Text] [Related]
19. Rescue therapy for lamivudine-resistant chronic hepatitis B: comparison between entecavir 1.0 mg monotherapy, adefovir monotherapy and adefovir add-on lamivudine combination therapy.
Kim HJ; Park JH; Park DI; Cho YK; Sohn CI; Jeon WK; Kim BI
J Gastroenterol Hepatol; 2010 Aug; 25(8):1374-80. PubMed ID: 20659226
[TBL] [Abstract][Full Text] [Related]
20. Hepatitis B virus quasispecies susceptibility to entecavir confirms the relationship between genotypic resistance and patient virologic response.
Baldick CJ; Eggers BJ; Fang J; Levine SM; Pokornowski KA; Rose RE; Yu CF; Tenney DJ; Colonno RJ
J Hepatol; 2008 Jun; 48(6):895-902. PubMed ID: 18362040
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]